Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|December 12, 2021
Expert Addresses How Addition of Umbralisib, Ublituximab Could Affect Treatement with Ibrutinib
Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.
Advertisement
In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.
She addressed how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
4
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
5